基于聚酰胺类树形分子前药的纳米给药系统在恶性肿瘤治疗中的应用

Polyamide dendrimer prodrug-based nanosystems in cancer therapy

高分子前药是前药分子设计策略中的一类重要分支,能够显著改善原药分子自身的性质缺陷。近年来,以聚酰胺-胺和肽类树形分子为代表的聚酰胺类树形分子因其自身的独特性质而被广泛应用于高分子前药的设计之中。聚酰胺类树形分子前药丰富的表面官能团和纳米级的分子尺寸,使其能与不同功能和特性的纳米材料相结合构建智能型树形分子前药纳米给药系统,以增加药物的体内循环稳定性、肿瘤富集能力、细胞穿透及组织渗透能力,进而实现肿瘤的多模式治疗和诊疗一体化。因此,本文重点归纳并总结了以聚酰胺类树形分子前药为基础,通过共价键合或非共价组装的方式构建新型抗肿瘤纳米给药系统的设计策略,为后续基于树形分子前药的纳米给药系统设计提供了新的思路和方法。

Polymer prodrugs are an important class of prodrugs,which can significantly improve the defects of the active drugs.Recently,polyamide dendrimers including poly(amidoamine)and peptide dendrimers have been widely used in the design of polymer prodrugs due to their unique properties.The abundant surface groups within a nanoscale volume of polyamide dendrimer prodrugs facilitate to combination with other multifunctional nanomaterials to construct smart dendrimer prodrug-based delivery systems.These systems can increase the circulation stability,enhance drug accumulation at tumor sites,and promote the cell penetration and tissue penetration of drugs.This review briefly summarized different strategies to construct novel polyamide dendrimer prodrug based nanosystems for cancer therapy,aiming to provide new perspective for the design of multifunctional prodrug based nanosystems for future nanomedicine.